← Back
$CRNX All transactions

Crinetics Pharmaceuticals, Inc.

A

$ Value

$0

Shares

32,000

Price

$0

Filed

Feb 25

Insider

Name

Schilke Tobin

Title

Chief Financial Officer

CIK

0001678984

Roles

Officer

Transaction Details

Transaction Date

2026-02-23

Code

A

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

84,834

Footnotes

The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027. | Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan. | The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.

Filing Info

Accession No.

0001628280-26-011728

Form Type

4

Issuer CIK

0001658247

Schilke Tobin's History

Date Ticker Type Value
2026-03-03 CRNX $266K
2026-02-23 CRNX A $0
2026-02-23 CRNX A $0

Other Insiders at CRNX (90d)

Insider Bought Sold Last
Vivaldi Coelho Rogerio $181K 2026-03-12
Schilke Tobin
Chief Financial Officer
$266K 2026-03-03
Okey Stephanie $119K 2026-03-03
Struthers Richard Scott
President & CEO
$822K 2026-03-16
Knight Jeff E.
Chief Dev. & Operating Officer
$3.4M 2026-04-08
Knight Jeff E.
Chief Operating Officer
$370K 2026-03-16
Betz Stephen F.
Chief Scientific Officer
$397K 2026-03-16
Kalofonos Isabel
Chief Commercial Officer
2026-02-23